

SYNTHESIS AND BIOLOGICAL ACTIVITY
OF SOME 6 α -FORMAMIDO PENICILLINS
MODIFIED IN THE 2 β -METHYL GROUP

Sir:

Recent publications^{1,2)} have highlighted the discovery of potent β -lactamase inhibitors by modification of the 2 β -methyl group in sulbactam. Similar modification of penicillins, with intact 6 β -acylamino substituents^{3,4)}, has been less successful in providing potent antibacterial agents. Earlier work in these laboratories has demonstrated how the introduction of a 6 α -formamido substituent⁵⁾ and a catechol⁶⁾ into penicillins gives rise to potent antibacterial agents with β -lactamase stability. In this paper we describe the incorporation of a number of substituents including a catechol, into the 2 β -methyl group of 6 α -formamido penicillins. The effect of the 2-substituent on antibacterial activity will be highlighted.

The key intermediate in the preparation of 2-modified 6 α -formamido penicillins is the azetidinone disulfide **4**. This was readily available from the protected penicillin⁵⁾ **1** by modification of a literature procedure⁷⁾. The presence of a 6 α -formamido substituent results in a mixture of α - and β -sulfoxides **2** and **3**⁸⁾ upon oxidation of **1** with *m*-chloroperoxybenzoic acid. Thermolysis of either of the pure isomers, or a mixture, in the presence of benzothiazole-2-thiol resulted in trapping of the intermediate sulfenic acid providing the disulfide **4**. The conversion of **4** into 2 β -substituted penicillins was achieved by two general methods. In the first, disulfide **4** was treated with a solution of bromine in carbon tetrachloride containing acetamide. The 2 β -bromomethyl penam **5a** was obtained in 63%

yield. Introduction of a 1-methyltetrazol-5-ylthio substituent was achieved by reaction of **5a** with sodium 1-methyltetrazol-5-yl thiolate in acetone-pH 6.9 phosphate buffer and provided **5b**. Treatment of **5a** with silver tetrafluoroborate in methanol resulted in replacement of bromo by methoxy to give **5c**. The second general method involved reaction of disulfide **4** with pre-formed complexes of iodine and the silver salt of a carboxylic acid⁹⁾. Thus benzoic acid provided the 2 β -benzoyloxymethyl derivative **5d**. Incorporation of a catechol was accomplished by reaction of **4** with iodine and silver 3,4-diacetoxybenzoate to give **5e**. Removal of the trichloroethoxycarbonyl protecting group from compounds **5b**~**5e** using zinc in pH 4 phosphate buffer provided the modified penicillin nuclei **6b**~**6e**. Coupling of **6b**~**6e** to *R*,2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonylamino]-2-phenylacetyl chloride to give **7b**~**7e** was significantly slower than for the parent nucleus **6g**. This may be a direct result of steric hindrance by the 2 β -substituent. Subsequently the preparation of a larger quantity of **5e** resulted in an inseparable 4:1 mixture of **5e** and a compound thought to be the isomeric cepham. After deprotection and acylation of the mixture compounds **7e** and the cepham **9** were separated by column chromatography. Hydrogenolysis of the benzyl ester in compounds **7b**~**7e** and **9** was followed by neutralisation providing the sodium salts **8b**~**8e** and **10**. The acetyl protecting groups of compound **8e** were removed by exposure to purified citrus acetyl esterase to give the catechol containing derivative **8f**.

The antibacterial activities of the 2-substituted penicillin derivatives, compared with that of the


Table 1. MICs^a of 2 β -substituted 6 α -formamido penicillins.

Organism	MIC (μ g/ml)						
	8b	8c	8d	8e	8f	8g	10
<i>Escherichia coli</i> DCO	16	>64	>64	0.12	0.12	4.0	>64
<i>E. coli</i> DCO RTEM	16	>64	>64	0.5	0.25	4.0	>64
<i>Enterobacter cloacae</i> N1	32	>64	>64	4.0	4.0	2.0	>64
<i>E. cloacae</i> P99	32	>64	>64	4.0	2.0	8.0	>64
<i>Klebsiella pneumoniae</i> T767	32	>64	>64	0.25	0.12	4.0	>64
<i>Pseudomonas aeruginosa</i> NCTC 10662	128	>64	>64	0.5	0.5	16	>64
<i>P. aeruginosa</i> Dalgleish	128	>64	>64	0.5	0.5	16	>64
<i>P. aeruginosa</i> Badia	>128	>64	>64	2.0	1.0	32	>64
<i>Staphylococcus aureus</i> Oxford	>128	>64	>64	>64	>128	>128	>64
<i>Streptococcus pyogenes</i> CN10	1.0	>64	64	8.0	4.0	2.0	>64


^a MIC determined in Iso-Sensitest Agar (Oxoid) inoculated with 10⁴ cfu/ml.

parent compound **8g** are shown in Table 1. It will be seen that incorporation of methoxy, benzyloxy or 1-methyltetrazol-5-ylthio groups into the β -methyl group results in compounds that are either inactive or show significantly reduced activity. In contrast to the poor activity of the benzyloxy


derivative **8d**, introduction of a catechol function as the 3,4-dihydroxybenzyloxy moiety provides a compound **8f**, with potent activity. The latter is substantially more active against strains of *Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* than the unsubstituted compound **8g**.




- 1 $n=0$
 2 $n=1$, α -isomer
 3 $n=1$, β -isomer




4




5a~5e








6b~6e, 6g



7b~7e



8b~8g

a $X=Br$ c $X=OMe$ g $X=H$ 

- 9 $R=CH_2Ph$ $R_1=Ac$
 10 $R=Na$ $R_1=Ac$

The increase in potency observed with the catecholic compound is probably the result of uptake of **8f** via the bacterial iron transport mechanism¹⁰.

The difference in intrinsic activities of the penam **8e** and cepham **10** systems is also shown in Table 1. While the former has potent activity the latter is essentially inactive despite the presence of a catechol function.

Acknowledgements

We are most grateful to Mrs. S. J. KNOTT and Miss J. LEMMER for the antibacterial susceptibility testing.

DAVID F. CORBETT
COLIN H. FRYDRYCH*
ROBERT SOUTHGATE
MICHAEL J. BASKER

Beecham Pharmaceuticals,
Chemotherapeutic Research Centre,
Brockham Park, Betchworth Surrey,
RH3 7AJ, UK

(Received February 5, 1990)

References

- HALL, T. W.; S. N. MAITI, R. G. MICETICH, P. SPEVAK, S. YAMABE, N. ISHIDA, M. KAJITANI, M. TANAKA & T. YAMASAKI: YTR-830 and related active β -lactamase inhibitors. In *Recent Advances in the Chemistry of β -Lactam Antibiotics*. Eds., A. G. BROWN & S. M. ROBERTS, pp. 242~254, Third International Symposium, Cambridge, 1985
- GOTTSTEIN, W. J.; L. B. CRAST, Jr., R. G. GRAHAM, U. J. HAYNES & D. N. MCGREGOR: Synthesis and β -lactamase inhibitory properties of 2 β -(chloromethyl)-2 α -methylpenam-3 α -carboxylic acid, 1,1-dioxide. *J. Med. Chem.* 24: 1531~1534, 1981
- KAMIYA, T.; T. TERAJI, M. HASHIMOTO, O. NAGAGUTI & T. OKU (Fujisawa): Penam and cepham derivatives and preparation thereof. U. S. P. 3,954, 732, May 4, 1976
- HASHIMOTO, M. & T. KAMIYA: Recent chemical modification of β -lactam antibiotics. *Jpn. J. Antibiotics* 30 (Suppl.): S218~S229, 1977
- SMALE, T. C.; A. W. GUEST, F. P. HARRINGTON, P. H. MILNER, R. J. PONSFORD & A. V. STACHULSKI: 6 α (7 α)-Formamido penicillins and cephalosporins. *J. Chem. Soc. Chem. Commun.* 1984: 1335~1336, 1984
- BASKER, M. J.; R. A. EDMONDSON, S. J. KNOTT, R. J. PONSFORD, B. SLOCOMBE & S. J. WHITE: In vitro antibacterial properties of BRL 36650, a novel 6 α -substituted penicillin. *Antimicrob. Agents Chemother.* 26: 734~740, 1984
- KAMIYA, T.; T. TERAJI, Y. SAITO, M. HASHIMOTO, O. NAKAGUCHI & T. OKU: Studies on β -lactam antibiotics. I. A novel conversion of penicillins into cephalosporins. *Tetrahedron Lett.* 1973: 3001~3004, 1973
- BRANCH, C. L.; M. J. PEARSON & T. C. SMALE: Direct incorporation of a 6 α (7 α)-formamido group into penicillins and cephalosporin sulphides and sulphoxides. *J. Chem. Soc. Perkin Trans. I* 1988: 2865~2873, 1988
- GOTTSTEIN, W. J.; U. J. HAYNES & D. N. MCGREGOR: Synthesis and β -lactamase inhibitory properties of 2 β -[(acyloxy)methyl]-2 α -methylpenam-3 α -carboxylic acid, 1,1-dioxides. *J. Med. Chem.* 28: 518~522, 1985
- CURTIS, N. A. C.; R. L. EISENSTADT, S. J. EAST, R. J. CORNFORD, L. A. WALKER & A. J. WHITE: Iron-regulated outer membrane proteins of *Escherichia coli* K-12 and mechanism of action of catechol-substituted cephalosporins. *Antimicrob. Agents Chemother.* 32: 1879~1886, 1988